i-LAB competition 2017: three Inria prizewinners in the field of medical technologies
Introduced in 1999 by the French Ministry for Research, and organised in partnership with the French public investment bank BpiFrance, the national competition to support the creation of innovative technology companies has honoured 62 prizewinners, including three from Inria.
19 years of business creation
The aim of the i-Lab competition is two-fold: to detect and foster business creation projects based on innovative technologies and to encourage the transfer of the research findings towards the socio-economic world. With over 1,820 companies created, 70% of which are still in operation, it has established itself as the main start-up initiative in France. For Frédérique Vidal, French Minister of Higher Education, Research and Innovation, this competition - where over half of the prizewinners of this 19th edition come from public research - is “a showcase of the excellence of French entrepreneurship”, but also “a means to bring public research and the socio-economic world even closer together.”
The three Inria prizewinning projects
Neurinnov: David Guiraud and the Camin project team
Offering a solution to patients seriously affected by pathologies for which therapy is no longer an option: this is the proposal ofNEURINNOV('NEUrostimulation généRIque et INNOVante', or generic and innovative neurostimulation). The solution, unique in Europe, is backed by Inria and relies on a partnership organised around a network of complementary expert physicians and industry players. The aim is to develop implantable neuroprostheses combining technology and expertise enabling, in the first instance, a solution to be found to severe sensory-motor disorders, with an envisaged extension to other similar pathologies.
inHeart: Jean-Marc Peyrat, former PhD student with the Asclepios project team
A spin-off of the electrophysiology and heart modelling institute IHU Liryc and Inria, inHEART proposes an equipped service that converts scanner and MRI images of patients into personalised virtual hearts. The result, integrated into existing interventional environments, provides cardiologists with a real-time 3D visualisation of their instruments. The result is safer, simpler, shorter and more effective treatment, thanks to direct visualisation. The personalised approach through imaging should make it possible to improve its results and generalise its use. The solution could be used for the treatment of ventricular tachycardia responsible for sudden deaths, atrial fibrillation or for selecting patients prior to pacemaker or defibrillator implants.
Therapanacea: Nikolaos Paragios, from the Galen project team
If, today, over 90% of patients requiring a replanning of their radiotherapy treatment continue to be treated according to an original plan that has become obsolete, it is because the appropriate tools to assist the medical teams did not exist. At the crossroads between research in applied mathematics and artificial intelligence,TheraAdaptRTintroduces the real-time recalculation of the radiation treatment plan, taking the patient's anatomy into account. This results in the development of intelligent digital tools in the form of a new software component dedicated to adaptive radiotherapy. By optimising the treatment chain the solution could, notably, allow for the treatment of at least twice as many patients, whilst increasing safety and chances of survival.